Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS^® will join Immuron’s product portfolio which includes the rapidly growing Travelan^® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.

Read more at globenewswire.com